EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease

Olle Ringdén, Behnam Sadeghi iD

Stem Cells · 2024

DOI: 10.1093/stmcls/sxae003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells, 2024. Verfasst von Olle Ringdén und 1 weiteren Autor:innen. Beteiligte Einrichtung: Translational Cell Therapy Research (TCR), Division of Pediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska …. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Cancer Society, Cancer Society in Stockholm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute graft-versus-host disease (GVHD) is a frequent and potentially life-threatening complication following allogeneic hematopoietic cell transplantation (HCT). Mesenchymal stromal cells (MSCs), rare precursors found in all body tissues, possess immunosuppressive properties and can inhibit alloreactivity both in vitro and in vivo. Two decades ago, we introduced bone marrow-derived (BM) MSCs as a novel therapy for acute GVHD. While some patients responded to BM-MSCs, the response was not universal. Commercially available BM-MSCs are now used for acute GVHD treatment in Canada, Japan, and New Zealand. The fetus is protected from the mother’s immune system by the placenta, and our research found that placenta-derived decidua stromal cells (DSCs) offer a stronger immunosuppressive effect than other sources of stromal cells. Safety studies in rabbits, rats, mice, and humans have shown negligible or no side effects from BM-MSCs or DSCs. In a phase I/II trial for severe acute GVHD, we treated 21 patients (median age, 49 years; range 1.6-72 years) with severe biopsy-proven gastrointestinal acute GVHD. The median cell dose of DSCs was 1.2 × 106 (range 0.9-2.9) cells/kg body weight, with a median of 2 (range 1-6) infusions given 1 week apart. The cell viability of DSCs was 93% (range, 69%-100%), and the median cell passage number was 4 (range, 2-4). All patients responded, with a complete response of acute GVHD in 11 patients and partial response in 10 and 1-year survival of 81%. Randomized trials are needed to prove the superiority of DSCs compared to ruxolitinib and/or other novel immunosuppressive therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationMesenchymal Stem Cell TransplantationMesenchymal Stem CellsAnimalsFemaleHumansMiceMiddle AgedRabbitsRatsAcute DiseaseDeciduaImmunosuppressive AgentsStromal CellsInfantChild, PreschoolChildAdolescentYoung AdultAdultAgedClinical Trials, Phase I as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

acute graft-versus-host diseaseallogeneic hematopoietic cell transplantationcell therapydesidua stromal cellsmesenchymal stromal cells

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Translational Cell Therapy Research (TCR), Division of Pediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Huddinge, Sweden.

ORCID-Profile: Behnam Sadeghi

Förderung

  • Swedish Cancer Society
  • Cancer Society in Stockholm

Zitieren

APA

Ringdén, O., & Sadeghi, B. (2024). Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease. Stem Cells. https://doi.org/10.1093/stmcls/sxae003

Vancouver

Ringdén O, Sadeghi B. Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease. Stem Cells. 2024. doi:10.1093/stmcls/sxae003

BibTeX
@article{Ringdn2024,
  author = {Ringdén, Olle and Sadeghi, Behnam},
  title = {Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease},
  journal = {Stem Cells},
  year = {2024},
  doi = {10.1093/stmcls/sxae003}
}
Kostenlos starten →